Anne Rabbitte (Fianna Fail)

They are already in that whole process but they cannot get early access. The compassionate grounds were stopped. It is on that element I am asking the question. There are so few patients in the rare disease category that they cannot compete with cancer patients or heart and stroke patients. The drug I have mentioned pertains to two a year. You cannot compete. Other countries have separate assessment pathway criteria for orphan medicines and early access programmes exist in other countries. Have Professor Barry and his team looked around to see what is happening elsewhere?